GlySure CEO to Present Clinical Trial Updates at Fall Medtech Industry Conferences
GlySure September 2012
AdvaMed 2012 and Medical Devices Summit Europe select GlySure to present progress toward U.S. and European regulatory approvals
GlySure Limited, developer of in-hospital continuous glucose monitoring (CGM) systems, will update the industry on its progress toward U.S. and European regulatory trials at two leading MedTech conferences this fall. GlySure CEO Christopher Jones will speak at the AdvaMed 2012 MedTech Conference on October 2 in Boston, and at the Medical Devices Summit Europe on November 14 in Dublin.
Tight Glycemic Control (TGC) in the Intensive Care Unit (ICU) has been shown to improve outcomes, reduce mortality and cut the cost of care. GlySure recently conducted human use trials that prove its system can continuously measure glucose levels across the entire human physiological range with an extremely high degree of accuracy and repeatability, which is key to effectively implementing TGC. The company is now preparing for its European and U.S. clinical regulatory trials.
The Advanced Medical Technology Association (AdvaMed) has selected GlySure as one of 70 medical device companies to present at its annual conference, which is attended by nearly 2,000 global MedTech executives, policy-makers, financiers, media and industry stakeholders. At the event, Jones will present the results of GlySure’s latest clinical trials and outline the company’s plans for CE and FDA regulatory trials in the coming months.
The producers of the 2012 Medical Devices Summit Europe have chosen Jones as one of 25 key MedTech leaders to share his insights on the global medical device industry. As a CEO with experience running both U.S. and European device companies, Jones will discuss “Strategies and Lessons Learned in International Distribution”.